Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®
Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8, 2023
Results showed an average AHI decrease of 73%
Mont-Saint-Guibert, Belgium – December 11, 2023, 7:30am CET / 1:30am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced data from a real-world case series evaluating treatment of three complete concentric collapse (CCC) patients with the Genio® hypoglossal nerve stimulation system. The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023. Results showed an average apnea-hypopnea index (AHI) decrease of 73% and Epworth Sleepiness Scale (ESS) decrease of 58%. There were no implant related adverse events.
Key Results:
- AHI: The AHI in Patient 1 decreased from 44/h to 5.6/h, in Patient 2 from 24/h to 11.2/h and ...